Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
MWN-AI** Summary
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a company focused on developing non-addictive pain management solutions and treatments for central nervous system disorders, has announced that Matthew Barnes, its senior director of portfolio management, will be presenting at the Outsourcing in Clinical Trials (OCT) Conference. This prominent global series connects over 1,000 industry leaders and professionals annually to share insights and strategies for enhancing clinical trial efficiency while managing costs effectively.
The OCT Conference serves as a platform for various stakeholders, including biotech and pharmaceutical companies, trial sponsors, and medical device manufacturers, to collaborate and discuss innovative approaches to clinical trial processes. In this context, Barnes will likely highlight Virpax's innovative methodologies and technological advancements aimed at improving clinical outcomes and patient experiences.
Virpax is actively developing several promising non-opioid and non-addictive pain management products. Its key candidates are Probudur™, a liposomal bupivacaine formulation designed for post-operative pain relief, and Envelta™, an intranasal drug targeting both acute and chronic pain. Furthermore, the company is also pursuing the development of NobrXiol™, which aims to deliver pharmaceutical-grade cannabidiol (CBD) for treating rare pediatric epilepsy.
In addition to his presentation, it’s worth noting that both Matthew Barnes and Dr. Sheila Mathias, Chief Scientific Officer, recently published articles in the DIA Global Forum and the OCT Handbook 2025, underscoring their expertise and contributions to the field.
Virpax is also exploring partnerships for its emerging non-prescription products, including AnQlar and Epoladerm™, positioning itself as a pioneer in addressing both pain management and viral infections. Investors and followers can stay updated with the company's progress through its official website and social media platforms.
MWN-AI** Analysis
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has garnered attention with the upcoming presentation by senior director Matthew Barnes at the Outsourcing in Clinical Trials Conference. This event is a significant hub for industry leaders to exchange insights and advancements, underscoring Virpax's commitment to innovation in the clinical trial landscape.
With a focus on developing non-addictive pain management therapies, Virpax is tapping into a growing market increasingly concerned with the opioid crisis. The acceptance of its proprietary technologies, such as the Probudur™ and Envelta™ candidates, signals the company's potential to fill a critical gap in safe and effective pain management options. Furthermore, collaborative agreements with prestigious entities like the National Institutes of Health (NIH) and the Department of Defense (DOD) lend credibility and may open doors for future partnerships and funding.
From an investment perspective, Virpax’s current pipeline showcases a compelling opportunity. The market for non-opioid analgesics is projected to expand, making Virpax's offerings particularly timely. However, investors should remain cautious regarding execution risk; successful clinical trials are pivotal, and the company will require additional capital to support ongoing studies—factors highlighted in their forward-looking statements.
Additionally, the publication of articles by Dr. Sheila Mathias and Barnes in recognized forums suggests that Virpax is not only active in clinical developments but also committed to contributing to the industry’s knowledge base, which may capture investor interest.
In summary, Virpax presents a noteworthy investment opportunity rooted in innovative therapies and strategic collaborations. However, potential investors should ensure they conduct thorough research into the company's clinical progress and market conditions, as the biotech sector can be volatile and impacted by regulatory hurdles. Thus, maintaining a watchful eye on developments following the conference will be crucial for informed decision-making.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference.
The Outsourcing in Clinical Trials (OCT) is a leading conference series for the clinical trial community that takes place worldwide and brings together 1,000+ industry leaders every year to share their success stories and discuss solutions for accelerating clinical trial timelines while maintaining reasonable costs.
OCT Series offers a valuable hub for biotech and pharma companies as well as trial sponsors, medical device manufacturers, and solution providers to safely collaborate, connect, and work towards success in their clinical trials.
In addition, the Company would like to congratulate Dr. Sheila Mathias, our Chief Scientific Officer, and Matthew Barnes on two articles that they published in the first DIA (Drug Information Association) Global Forum and an additional article that they published in Outsourcing In Clinical Trials (OCT) Handbook 2025.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.
Forward-Looking Statements
This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250131733041/en/
Investor Contact:
info@virpaxpharma.com
FAQ**
What competitive advantages does Virpax Pharmaceuticals Inc. (VRPX) have in its proprietary technologies for non-addictive pain management compared to other firms in the biotech space?
How does Virpax Pharmaceuticals Inc. (VRPX) plan to secure the additional capital necessary to complete the clinical trials for its promising drug candidates?
What outcomes is Virpax Pharmaceuticals Inc. (VRPX) anticipating from Matthew Barnes' presentation at the Outsourcing in Clinical Trials Conference that could impact investor sentiment?
Can you elaborate on the CRADAs Virpax Pharmaceuticals Inc. (VRPX) has with the NIH and DOD, and how these partnerships might enhance the company's development pipeline?
**MWN-AI FAQ is based on asking OpenAI questions about Virpax Pharmaceuticals Inc. (NASDAQ: VRPX).
NASDAQ: VRPX
VRPX Trading
70.13% G/L:
$0.35 Last:
148,800 Volume:
$0.20 Open:
